|
Balance Sheet Cash Flow Statement 3 N. Dunlap St., Van Vleet Bldg. Memphis, TN 38163 TN Tel. 901-523-9700 Fax 901-523-9772 |
Type: Public
On the web:
http://www.gtxinc.com
Employees:
147
Employee growth: 32.4%
GTx knows hormones are just as important to men as they are to women. The company develops therapies targeting estrogens and androgens for prostate cancer and other diseases in the arena of men's health. GTx's lead drug candidate, Acapodene, could prevent men who have been identified with certain precancerous conditions from developing prostate cancer. The drug may also be useful in treating osteoporosis, hot flashes, and other side effects of androgen-deprivation therapy (a treatment for advanced prostate cancer). To fund its work, GTx sells Fareston, a drug for metastatic breast cancer. Chairman J.R. Hyde owns nearly one-third of the company.
Key numbers for fiscal year ending December, 2008:
Sales: $13.5M
One year growth: 89.8%
Net income: ($51.8)M
Officers:
Chairman: Joseph R. (J. R.) Hyde III
Vice Chairman and CEO: Mitchell S. Steiner
President, COO, and Director: Marc S. Hanover
Competitors:
AstraZeneca
Eli Lilly
GlaxoSmithKline
